Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

3(75.0%)

Phase 3

1(25.0%)

4Total

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05794139Phase 2Active Not Recruiting

Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

Role: lead

NCT06414954Phase 2Recruiting

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Role: lead

NCT06482437Phase 2Completed

Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease

Role: lead

NCT05919407Phase 3Unknown

Pyridostigmine and Amifampridine for Myasthenia Gravis

Role: collaborator

NCT04980807Completed

Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls

Role: lead

NCT04904926Completed

Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults

Role: lead

All 6 trials loaded